ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06855 ASCENTAGE-B

Closed 03-11 16:08:15

46.660

-0.320

-0.68%

High47.840	Low46.020	Vol1.35M
Open47.520	D1 Closing46.980	Amplitude3.87%
Mkt Cap17.40B	Tradable Cap17.40B	Total Shares373.00M
T/O62.94M	T/O Rate0.36%	Tradable Shares373.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"ASCENTAGE-B","latestPrice":46.66,"timestamp":1773216495006,"preClose":46.98,"halted":0,"volume":1345600,"delay":0,"changeRate":-0.006811409110259691,"floatShares":373000000,"shares":373000000,"eps":-1.342217,"marketStatus":"Closed","change":-0.32,"latestTime":"03-11 16:08:15","open":47.52,"high":47.84,"low":46.02,"amount":62935508,"amplitude":0.03874,"askPrice":46.66,"askSize":4900,"bidPrice":46.64,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-3.405,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773279000000},"marketStatusCode":5,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":46.98,"openAndCloseTimeList":[[1773192600000,1773201600000],[1773205200000,1773216000000]],"volumeRatio":0.535713,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"2618447509","title":"Ascentage Pharma Group International Schedules Full-Year 2025 Unaudited Financial Results Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2618447509","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618447509?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:02","pubTimestamp":1773230570,"startTime":"0","endTime":"0","summary":"Ascentage Pharma said it will release its full year 2025 unaudited results and provide business updates at 7:00 pm EDT on March 25, 2026 / 7:00 am HKT on March 26, 2026. The company will host a Chinese  investor webcast with Q&A at 10:00 pm EDT on March 25, 2026 / 10:00 am HKT on March 26, 2026; registration is available here. An English investor webcast is scheduled for 8:00 am EDT / 8:00 pm HKT on March 26, 2026; registration is available here.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL73MRp2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","IE00B64PRP62.GBP","SG9999014021.USD","BK1574","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014039.USD","LU2095319765.USD","BK4585","SG9999014005.SGD","LU2210149790.SGD","LU0314104364.USD","SG9999014013.SGD","BK4112","BK4588","IE00B3QW5Z07.USD","BK1161","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2618944113","title":"Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618944113?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:00","pubTimestamp":1773230404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA4NCFZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","06855"],"gpt_icon":0},{"id":"1124006260","title":"ASCENTAGE-B (06855) Announces February 2026 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1124006260","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124006260?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:28","pubTimestamp":1772749722,"startTime":"0","endTime":"0","summary":"In February 2026, Ascentage Pharma Group International reported an authorized share capital of 500.00 million ordinary shares at a par value of USD 0.0001, totaling USD 50,000. The total number of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"gpt_icon":0},{"id":"2614149338","title":"Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2614149338","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614149338?lang=en_us&edition=fundamental","pubTime":"2026-02-28 17:31","pubTimestamp":1772271115,"startTime":"0","endTime":"0","summary":"Recent share move and business snapshot\nAscentage Pharma Group International (SEHK:6855) has seen its share price move recently, with a 1 day return of about 1.4% and a decline of roughly 26.9% over the past 3 months, drawing attention to its clinical stage biotech profile.\nSee our latest analysis for Ascentage Pharma Group International.\nLooking beyond the latest move, the share price has recorded a 4.9% decline over the past month and a 26.9% decline over the past quarter, while the 1 year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2613784767","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613784767","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613784767?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851652,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL8237Kb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","BK4112","NDAQ","IE00BKPKM429.USD","06855","BK1574","LU2210149790.SGD","BK1161","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","LU2095319765.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2612547489","title":"Is Ascentage Pharma Group International (SEHK:6855) Pricing Reflect A 23.3% One‑Year Gain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2612547489","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612547489?lang=en_us&edition=fundamental","pubTime":"2026-02-19 10:28","pubTimestamp":1771468088,"startTime":"0","endTime":"0","summary":"If you are wondering whether Ascentage Pharma Group International's current share price still makes sense, this article will walk through how its value stacks up using several common valuation tools.\nThe stock closed at HK$46.68, with a 7 day return of a 2% decline, a 30 day return of an 8% decline and a 1 year return of 23.3%, which may catch the eye of investors thinking about both risk and opportunity.\nRecent trading interest has been shaped by ongoing attention on the biotech and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-sehk6855-pricing-ref","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-sehk6855-pricing-ref","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2611692112","title":"Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2611692112","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611692112?lang=en_us&edition=fundamental","pubTime":"2026-02-14 16:28","pubTimestamp":1771057713,"startTime":"0","endTime":"0","summary":"Why Ascentage Pharma Group International (SEHK:6855) Is Drawing Investor Attention\nAscentage Pharma Group International (SEHK:6855) has come onto investor radars after recent share price moves, with a 1 day return of 2.4% and a 7 day gain of 1.3%.\nThese short term shifts contrast with a month decline of 12.8% and a past 3 months drop of 29.7%. This has prompted investors to reassess how the current price of HK$47.5 lines up with the company’s fundamentals.\nSee our latest analysis for...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-group-international-sehk6855-valu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2610658213","title":"Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610658213","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610658213?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:02","pubTimestamp":1770642125,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDLxW7q6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4585","BK1574","BK4588","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","BK1161","NDAQ","SG9999014021.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","06855","LU0314104364.USD","SG9999014039.USD","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2609533605","title":"Ascentage Pharma Announces Ind Clearance by the China Cde for Btk Degrader Apg-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609533605?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:31","pubTimestamp":1770334273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nFWN3Z11VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2609336205","title":"China erteilt Ascentage Pharma IND-Genehmigung für BTK-Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2609336205","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609336205?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:30","pubTimestamp":1770334216,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL4byFS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","SG9999014039.USD","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","LU2095319765.USD","SG9999014021.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK1161","BK1574","LU2210150020.SGD","BK4112","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585"],"gpt_icon":0},{"id":"1101720697","title":"Ascentage Pharma (06855) Announces January 2026 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1101720697","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101720697?lang=en_us&edition=fundamental","pubTime":"2026-02-05 23:03","pubTimestamp":1770303829,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (stock code: 06855) has released its monthly return for the period ended 31 January 2026. The company’s authorized share capital remains at 500,000,000 ordinary...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"gpt_icon":0},{"id":"1128142501","title":"ASCENTAGE-B Stock Surges Over 3% in Intraday Trading as BTK Degrader Class 1 New Drug APG-3288 Tablets Gain Clinical Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1128142501","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128142501?lang=en_us&edition=fundamental","pubTime":"2026-02-04 11:12","pubTimestamp":1770174738,"startTime":"0","endTime":"0","summary":"Shares of ASCENTAGE PHARMA GROUP - B (06855) climbed more than 3% during the trading session. At the time of writing, the stock was up 1.38%, trading at HK$45.88, with a turnover of HK$36.975...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","BK1161","06855","BK4139","APG","AAPG","LU1923622291.USD","BK1574","LU2125909916.SGD","BK4129"],"gpt_icon":0},{"id":"2603629889","title":"Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2603629889","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603629889?lang=en_us&edition=fundamental","pubTime":"2026-01-15 09:25","pubTimestamp":1768440322,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire  on January 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLbJhWXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","BK1574","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014021.USD","BK4588","IE00B3QW5Z07.USD","06855","SG9999014039.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","LU0314104364.USD","BK4585","SG9999014005.SGD","BK1161","NDAQ"],"gpt_icon":0},{"id":"2602396695","title":"A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2602396695","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602396695?lang=en_us&edition=fundamental","pubTime":"2026-01-10 22:17","pubTimestamp":1768054675,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that its BTK-targeted protein degrader APG-3288 received U.S. FDA IND clearance, allowing a global Phase I trial in relapsed or refractory B-cell malignancies.\nSee our latest analysis for Ascentage Pharma Group International.\nThe FDA IND clearance for APG-3288 comes as Ascentage Pharma’s share price sits at HK$54.95, with a 1-day share price return of 1.20% and a 7-day share price return of 7.96%,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/a-look-at-ascentage-pharma-group-internationals-valuation-af","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06855","BK1574","APG","BK4129","IND","LU1923622291.USD","LU2125909759.SGD","LU2125909916.SGD","BK1161"],"gpt_icon":0},{"id":"1146349455","title":"Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=1146349455","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146349455?lang=en_us&edition=fundamental","pubTime":"2026-01-07 11:10","pubTimestamp":1767755435,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) rose nearly 4%, and as of the time of writing, it was up 3.69% to HK$53.4, with a turnover of HK$61.6418 million.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AAPG","BK4129","BK1161","LU2125909916.SGD","LU1923622291.USD","06855","APG","BK1574","LU2125909759.SGD"],"gpt_icon":0},{"id":"2601844717","title":"FDA Clears IND for Ascentage Pharma’s BTK Degrader APG-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844717","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601844717?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747615,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has received Investigational New Drug  clearance from the U.S. Food and Drug Administration  for its novel next-generation Bruton tyrosine kinase -targeted protein degrader, APG-3288. This regulatory approval enables the company to initiate a global, multicenter Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-3288 in patients with relapsed or refractory B-cell malignancies. The clearance marks a significant milestone in Ascentage Pharma’s efforts to expand its pipeline of innovative therapies for hematologic malignancies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL4qKXD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06855","BK4585","LU2210149790.SGD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","BK4112","SG9999014013.SGD","IE00B64PRP62.GBP","BK4588","LU2210150020.SGD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","IE00B3QW5Z07.USD","SG9999014021.USD"],"gpt_icon":0},{"id":"2601844774","title":"Ascentage Pharma Announces Ind Clearance by the U.S. Food and Drug Administration for Btk Degrader Apg-3288","url":"https://stock-news.laohu8.com/highlight/detail?id=2601844774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601844774?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:00","pubTimestamp":1767747600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA4NDY9B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06855","BK1574","BK1161"],"gpt_icon":0},{"id":"1168013082","title":"ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1168013082","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168013082?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:50","pubTimestamp":1767106220,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that Dr. Debra Yu will be appointed as an additional member of the Board Nomination Committee, effective December 26, 2025. Dr. David Sidransky will be...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK1161","BK1574","BK4139","06855"],"gpt_icon":0},{"id":"2595713514","title":"Ascentage Pharma Group International Files Director List to HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713514","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595713514?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:46","pubTimestamp":1767105999,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL4Nw1Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2595713803","title":"Ascentage Pharma Appoints Dr. Debra Yu to Nomination Committee and Dr. David Sidransky as Lead Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713803","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595713803?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:42","pubTimestamp":1767105768,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has announced changes to its board and committees. Dr. Debra Yu has been appointed as an additional member of the Nomination Committee, which will now include Dr. David Sidransky as chairman, along with Mr. Ren Wei and Marc E. Lippman. The company also announced the establishment of a Research and Development Committee and the appointment of a Lead Independent Non-Executive Director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL5thV3d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK1574","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":0.1065},{"period":"1month","weight":0.0021},{"period":"3month","weight":-0.2037},{"period":"6month","weight":-0.3942},{"period":"1year","weight":0.2561},{"period":"ytd","weight":-0.1009}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":-0.0226},{"period":"3month","weight":0.0164},{"period":"6month","weight":-0.0048},{"period":"1year","weight":0.0915},{"period":"ytd","weight":0.0129}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.091562},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.090219},{"month":4,"riseRate":0.833333,"avgChangeRate":0.119495},{"month":5,"riseRate":0.5,"avgChangeRate":0.054537},{"month":6,"riseRate":0.833333,"avgChangeRate":0.306068},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.077026},{"month":8,"riseRate":0.833333,"avgChangeRate":0.051008},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.083178},{"month":10,"riseRate":0.5,"avgChangeRate":0.039816},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"ASCENTAGE-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCENTAGE-B(06855) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCENTAGE-B,06855,ASCENTAGE-B股票,ASCENTAGE-B股票老虎,ASCENTAGE-B股票老虎国际,ASCENTAGE-B行情,ASCENTAGE-B股票行情,ASCENTAGE-B股价,ASCENTAGE-B股市,ASCENTAGE-B股票价格,ASCENTAGE-B股票交易,ASCENTAGE-B股票购买,ASCENTAGE-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCENTAGE-B(06855) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}